Dabigatran etexilate

Dabigatran Etexilate is the prodrug of dabigatran, a potent, nonpeptidic small molecule that specifically and reversibly inhibits both free and clot-bound thrombin by binding to the active site of the thrombin molecule.An anticoagulant from the

Dabigatran Etexilate is the prodrug of dabigatran, a potent, nonpeptidic small molecule that specifically and reversibly inhibits both free and clot-bound thrombin by binding to the active site of the thrombin molecule.An anticoagulant from the

Dabigatran Etexilate is the prodrug of dabigatran, a potent, nonpeptidic small molecule that specifically and reversibly inhibits both free and clot-bound thrombin by binding to the active site of the thrombin molecule.An anticoagulant from the

DABIGATRAN ETEXILATE ACID

A double prodrug that undergoes in vivo hydrolytic cleavage to produce dabigatran, a potent thrombin inhibitor (Ki = 4.5 nM) shows antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action.

A double prodrug that undergoes in vivo hydrolytic cleavage to produce dabigatran, a potent thrombin inhibitor (Ki = 4.5 nM) shows antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action.

A double prodrug that undergoes in vivo hydrolytic cleavage to produce dabigatran, a potent thrombin inhibitor (Ki = 4.5 nM) shows antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action.

Dabigatran ethyl ester hydrochloride is a potent inhibitor of ribosyldihydronicotinamide dehydrogenase ( NQO2 ) with an IC 50 value of 0.8 μM and a thrombin inhibitor.In VitroThe K i of dabigatran (ethyl ester hydrochloride) toward NQO2 is 0.9 μM

A potent thrombin inhibitor (Ki = 4.5 nM) also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases has poor bioavailability after oral administration.

A potent thrombin inhibitor (Ki = 4.5 nM) also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases has poor bioavailability after oral administration.

A potent thrombin inhibitor (Ki = 4.5 nM) also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases has poor bioavailability after oral administration.

A potent thrombin inhibitor (Ki = 4.5 nM) also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases has poor bioavailability after oral administration.